Association of the Pretreatment Lung Immune Prognostic Index with Survival Outcomes in Advanced Hepatocellular Carcinoma Patients Treated with PD-1 Inhibitors

PURPOSE: At present, there are no validated biomarkers that can predict whether patients with advanced hepatocellular carcinoma (aHCC) are likely to benefit from anti-PD-1 therapy. We aimed to determine whether lung immune prognostic index (LIPI) is associated with outcomes in patients with aHCC tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Shixue, Huang, Ziwei, Jia, Wangping, Tao, Haitao, Zhang, Sujie, Ma, Junxun, Liu, Zhefeng, Wang, Jinliang, Wang, Lijie, Cui, Pengfei, Zhang, Zhibo, Huang, Di, Wu, Zhaozhen, Zheng, Xuan, Hu, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646485/
https://www.ncbi.nlm.nih.gov/pubmed/33173757
http://dx.doi.org/10.2147/JHC.S277453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646485/
https://www.ncbi.nlm.nih.gov/pubmed/33173757
http://dx.doi.org/10.2147/JHC.S277453

Ejemplares similares